Why converging regulation, sustainability and biologics are rewriting the specification for pharmaceutical materials – and why no company will solve it alone.
The pharmaceutical industry is experiencing not one disruption but several at once. PFAS restriction, the propellant transition, expiring device patents and the relentless rise of biologics are colliding – and each is quietly asking the same question of the components that touch our medicines. The answer will not come from a single supplier, but from an ecosystem willing to innovate together.
Walk the halls of CPHI or the Drug Delivery to the Lungs (DDL) conference this autumn and one theme follows you from stand to stand: change. For two decades the materials in our inhalers, injectors, vials and filling lines were treated as settled science. That stability is ending. A cluster of regulatory, environmental and clinical pressures is arriving at once, and beneath every one lies the same question: is the material of construction still fit for what we now ask of it?
The honest answer is rarely “exotic materials everywhere.” For most components, metals, elastomers and commodity plastics remain perfectly adequate, and highperformance polymers have historically been reserved for a device’s few genuinely demanding corners – the high-pressure dosing chamber of a soft mist inhaler being the classic example. What is changing is that those corners are multiplying. A useful rule of thumb: when three demanding requirements must be met at once – strength, say, with chemical inertness and a tight, stable tolerance – a specialist polymer such as PEEK (polyetheretherketone) begins to earn its place. It is worth holding that test in mind through what follows – asking not only what each pressure breaks, but what might quietly fix it.
PFAS: From the Seal to the Coated Stopper
Fluoropolymers such as PTFE and PVDF are everywhere in pharmaceutical operations – in valve seats, seals, gaskets and O-rings on filling lines, in non-stick coatings, and, critically, in the spray-coated stoppers and plungers that protect injectable biologics. As PFAS restriction tightens across Europe, forward-looking teams are mapping where those chemistries sit in their bill of materials. Substitution is not uniform: where PTFE is chosen for its lubricity and non-stick behaviour, it is hard to match without real development work. But where a fluoropolymer is doing a sealing or chemical-resistance job, credible nonfluorinated options exist. PEEK, for example, is used for seals, valves and connectors across temperature extremes – from cryogenic handling to high-temperature aseptic processing – and its very low leachables suit it wherever purity in contact with the drug matters most. The lesson: a bill of materials can be unpicked function by function, not all at once.
